• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form F-6EF filed by COMPASS Pathways Plc

    5/15/24 4:37:31 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CMPS alert in real time by email
    F-6EF 1 e663584_f6ef-cp.htm

     

    As filed with the Securities and Exchange Commission on May 15, 2024

    Registration No. 333-[●] 

       

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM F-6

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES EVIDENCED BY 

    AMERICAN DEPOSITARY RECEIPTS

     

     

     

    Compass PATHWAYS PLC  

    (Exact name of issuer of deposited securities as specified in its charter)

     

     

     

    N/A 

    (Translation of issuer’s name into English)

     

     

     

    England and Wales 

    (Jurisdiction of incorporation or organization of issuer)

     

     

     

    CITIBANK, N.A. 

    (Exact name of depositary as specified in its charter)

     

     

     

    388 Greenwich Street

    New York, New York 10013

    (877) 248-4237 

    (Address, including zip code, and telephone number, including area code, of depositary’s principal executive offices)

     

     

     

    Teri Loxam

    Compass Pathways plc

    44 West 37th Street, 7th Floor

    New York, New York 10014

    (716) 676-6461

    (Address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Benjamin K. Marsh

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, Massachusetts 02210

    +1 (617) 570-1000

     

    Herman H. Raspé, Esq.

    Patterson Belknap Webb & Tyler LLP
    1133 Avenue of the Americas
    New York, New York 10036

    212-336-2301

     

     

     

      It is proposed that this filing become effective under Rule 466:  ☒ immediately upon filing.
         ☐

    on (Date) at (Time). 

     

    If a separate registration statement has been filed to register the deposited shares, check the following box : ☐

     

     

     

    CALCULATION OF REGISTRATION FEE

     

    Title of Each Class of
    Securities to be Registered
    Amount to be
    Registered

    Proposed Maximum

    Aggregate Price Per Unit*

    Proposed Maximum

    Aggregate Offering Price**

    Amount of

    Registration Fee

     

    American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) ordinary share of Compass Pathways plc. 100,000,000 ADSs $5.00 $5,000,000.00 $738.00
     

    *     Each unit represents 100 ADSs.

    **   Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of ADSs.

     

     

     

     

     

     

    This Registration Statement may be executed in any number of counterparts, each of which shall be deemed an original, and all of such counterparts together shall constitute one and the same instrument.

      

     

    ii

     

     

    PART I

     

    INFORMATION REQUIRED IN PROSPECTUS

     

    Cross Reference Sheet

     

    Item 1.DESCRIPTION OF SECURITIES TO BE REGISTERED

     

    Item Number and Caption

     

    Location in Form of American

    Depositary Receipt (“Receipt”)
    Filed Herewith as Prospectus

         
    1. Name of Depositary and address of its principal executive office   Face of Receipt -  Introductory Article.
           
    2. Title of Receipts and identity of deposited securities   Face of Receipt  - Top Center.
             
    Terms of Deposit:    
         
      (i) The amount of deposited securities represented by one American Depositary Share ("ADSs")   Face of Receipt  - Upper right corner.
             
      (ii) The procedure for voting, if any, the deposited securities   Reverse of Receipt  - Paragraphs (17) and (18).
             
      (iii) The collection and distribution of dividends   Reverse of Receipt - Paragraph (15).
             
      (iv) The transmission of notices, reports and proxy soliciting material   Face of Receipt  - Paragraph (14);
    Reverse of Receipt - Paragraph (18).
             
      (v) The sale or exercise of rights  

    Reverse of Receipt – Paragraphs (15) and (17).

             
      (vi) The deposit or sale of securities resulting from dividends, splits or plans of reorganization  

    Face of Receipt - Paragraphs (3) and (6);

    Reverse of Receipt - Paragraphs (15) and (17).

             
      (vii) Amendment, extension or termination of the deposit agreement   Reverse of Receipt - Paragraphs (23) and (24) (no provision for extensions).

     

     

    I-1

     

     

    Item Number and Caption 

     

    Location in Form of American

    Depositary Receipt (“Receipt”)
    Filed Herewith as Prospectus 

             

      (viii) Rights of holders of Receipts to inspect the transfer books of the Depositary and the list of holders of ADSs   Face of Receipt - Paragraph (14).
             
      (ix) Restrictions upon the right to deposit or withdraw the underlying securities   Face of Receipt – Paragraphs (2), (3), (4), (6), (7), (9) and (10).
             
      (x) Limitation upon the liability of the Depositary  

    Face of Receipt - Paragraph (8);

    Reverse of Receipt - Paragraphs (20) and (21).

             
    3.     Fees and charges which may be imposed directly or indirectly on holders of ADSs   Face of Receipt - Paragraph (11).
             
    Item 2.  AVAILABLE INFORMATION   Face of Receipt - Paragraph (14).

     

    The Company is subject to the periodic reporting requirements of the United States Securities Exchange Act of 1934, as amended, and, accordingly, files certain reports with, and submits certain reports to, the United States Securities and Exchange Commission (the “Commission”). These reports can be retrieved from the Commission’s internet website (www.sec.gov), and can be inspected and copied at the public reference facilities maintained by the Commission at 100 F Street, N.E., Washington D.C. 20549.

      

    I-2

     

     

     

     

    PROSPECTUS

     

    The Prospectus consists of the form of American Depositary Receipt included as Exhibit A to the Deposit Agreement filed as Exhibit (a) to this Registration Statement on Form F-6 and is incorporated herein by reference.

     

     

    I-3

     

     

    PART II

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 3.EXHIBITS

     

    (a)Deposit Agreement, dated as of September 22, 2020, by and among Compass Pathways plc (the “Company”), Citibank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners of American Depositary Shares issued thereunder (“Deposit Agreement”). ___ Filed herewith as Exhibit (a).

     

    (b)(i)Restricted ADS Letter Agreement, dated as of September 24, 2020, by and between the Company and the Depositary (the “Restricted ADS Letter Agreement”) – Filed herewith as Exhibit (b)(i).

     

    (b)(ii)Amended and Restated Restricted ADS Letter Agreement, dated as of December 28, 2021, by and between the Company and the Depositary (the “Amended and Restated Restricted ADS Letter Agreement”) – Filed herewith as Exhibit (b)(ii).

     

    (b)(iii)At-the-Market Letter Agreement, dated as of October 12, 2022, by and between the Company and the Depositary (the “ATM Letter Agreement”). – Filed herewith as Exhibit (b)(iii).

     

    (b)(iv)Omnibus Restricted ADS Letter Agreement, dated as of August 18, 2023, by and between the Company and the Depositary (the “Omnibus Restricted ADS Letter Agreement”) – Filed herewith as Exhibit (b)(iv).

     

    (b)(v)Second Amended and Restated Restricted ADS Letter Agreement - Affiliate and Restricted Securities Series Letter Agreement, dated as of August 18, 2023, by and between the Company and the Depositary (the “Affiliate Restricted ADS Letter Agreement”) – Filed herewith as Exhibit (b)(v).

     

    (b)(vi)PIPE Securities Series Letter Agreement, dated as of August 18, 2023, by and between the Company and the Depositary (the “PIPE Letter Agreement”) – Filed herewith as Exhibit (b)(vi).

     

    (b)(vii)Warrant Exercise Series Letter Agreement, dated as of August 18, 2023, by and between the Company and the Depositary (the “Warrant Letter Agreement”) – Filed herewith as Exhibit (b)(vii).

     

    (c)Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. ___ None.

      

    II-1

     

     

    (d)Opinion of counsel for the Depositary as to the legality of the securities to be registered. ___ Filed herewith as Exhibit (d).

     

    (e)Certificate under Rule 466. ___ Filed herewith as Exhibit (e).

     

    (f)Powers of Attorney for certain officers and directors and the authorized representative of the Company. ___ Set forth on the signature pages hereto.

      

    II-2

     

     

    Item 4.UNDERTAKINGS

     

    (a)The Depositary undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of ADSs, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.

     

    (b)If the amount of fees charged is not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an ADS thirty (30) days before any change in the fee schedule.

     

     

    II-3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity to be created by the Deposit Agreement, by and among Compass Pathways plc, Citibank, N.A., as depositary, and all Holders and Beneficial Owners of American Depositary Shares to be issued thereunder, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on the 15th day of May, 2024.

      

     

    Legal entity created by the Deposit Agreement under which the American Depositary Shares registered hereunder are to be issued, each American Depositary Share representing the right to receive one (1) ordinary share of Compass Pathways plc.

     

    CITIBANK, N.A., solely in its capacity as Depositary 

         
      By: /s/ Joseph Connor
      Name:  Joseph Connor
      Title:   Attorney-in-Fact

     

     

    II-4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, Compass Pathways plc certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Registration Statement on Form F-6 to be signed on its behalf by the undersigned thereunto duly authorized, in the City of London, United Kingdom, on May 15, 2024.

     

     

    Compass PATHWAYS plc 

         
      By:    /s/ Kabir Nath
     

    Name: Kabir Nath

    Title: Chief Executive Officer 

     

     

    II-5

     

     

    POWERS OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Kabir Nath and Teri Loxam to act as his/her true and lawful attorney-in-fact and agent, with full power of substitution, for him/her and in his/her name, place and stead, in any and all such capacities, to sign any and all amendments, including post-effective amendments, and supplements to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the United States Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as s/he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his/her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form F-6 has been signed by the following persons in the following capacities on May 15, 2024.

     

    Signature   Title
         
    /s/ Kabir Nath   Chief Executive Officer and Director
    Kabir Nath   (Principal Executive Officer)
         
    /s/ Teri Loxam   Chief Financial Officer (Principal Financial Officer
    Teri Loxam   and Principal Accounting Officer)
         
    /s/ David Norton   Chair of Board of Director
    David Norton    
         
    /s/ Annalisa Jenkins   Director
    Annalisa Jenkins, MBBS    
         
    /s/ Daphne Karydas   Director
    Daphne Karydas    
         
    /s/ Thomas Lönngren   Director
    Thomas Lönngren    
         
    /s/ Linda McGoldrick   Director
    Linda McGoldrick, Ph.D.    
         
    /s/ Robert McQuade   Director
    Robert McQuade    
         
    /s/ Wayne J. Riley   Director
    Wayne J. Riley    
         

     

    II-6

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, Compass Pathways plc has duly caused this registration statement to be signed by the following duly authorized representative in the United States on May 15, 2024:

      

    Authorized U.S. Representative 

     
       

    COMPASS PATHWAYS PLC

     
         
    By:    /s/ Teri Loxam  

     

    Name: Teri Loxam

    Title: Chief Financial Officer

     

     

     

    II-7

     

     

    Index to Exhibits

     

    Exhibit Document

    Sequentially

    Numbered Page

         

    (a)

    Deposit Agreement

     
         
    (b)(i) Restricted ADS Letter Agreement  
         
    (b)(ii) Amended and Restated Restricted ADS Letter Agreement  
         
    (b)(iii) ATM Letter Agreement  
         
    (b)(iv) Omnibus Restricted ADS Letter Agreement  
         
    (b)(v) Affiliate Restricted ADS Letter Agreement  
         
    (b)(vi) PIPE Letter Agreement  
         
    (b)(vii) Warrant Letter Agreement  
         
    (d) Opinion of counsel to the Depositary  
         
    (e) Rule 466 Certificate  
         
         
         
         

     

     

    Get the next $CMPS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMPS

    DatePrice TargetRatingAnalyst
    12/10/2025$15.00Perform → Outperform
    Oppenheimer
    6/23/2025$11.00 → $6.00Outperform → In-line
    Evercore ISI
    2/27/2025$11.00Buy
    Stifel
    7/23/2024$23.00Outperform
    RBC Capital Mkts
    4/1/2024$30.00Overweight
    Morgan Stanley
    12/12/2023$16.00Buy
    Deutsche Bank
    11/21/2022$33.00Buy
    Berenberg
    11/1/2022$34.00Buy
    Loop Capital
    More analyst ratings

    $CMPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Nath Kabir covered exercise/tax liability with 16,181 units of Ordinary Shares, decreasing direct ownership by 7% to 205,121 units (SEC Form 4)

    4 - COMPASS Pathways plc (0001816590) (Issuer)

    2/3/26 5:19:56 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Jonas Jeffrey M

    4 - COMPASS Pathways plc (0001816590) (Issuer)

    10/31/25 6:57:23 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Jonas Jeffrey M

    3 - COMPASS Pathways plc (0001816590) (Issuer)

    10/31/25 6:52:34 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

    FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trial Compass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD) Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted i

    1/7/26 6:30:00 AM ET
    $CMPS
    $HTGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360

    Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaboration, with Radial Health, Inc., a growing national network of interventional psychiatry practices leveraging technology and operations expertise to optimize models of care delivery. This collaboration will further help to inform the development of scalable delivery models for investigational COMP360 psilocybin treatment, if FDA approved. The agreement with Radial expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with mental

    1/6/26 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

    Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will host a webinar to discuss the company's commercial preparations for treatment-resistant depression (TRD) and clinical trial plans for post-traumatic stress disorder (PTSD) from 10:00-11:30 am ET on January 7, 2026. The discussion will include KOL and industry leaders' perspectives on the current treatment landscape and the significant unmet need in treating both TRD and PTSD. The company's collaboration partners will discuss patient care pathways, provider economics for multi-hour treatments, and the develop

    12/9/25 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    COMPASS Pathways upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded COMPASS Pathways from Perform to Outperform and set a new price target of $15.00

    12/10/25 8:10:44 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COMPASS Pathways downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded COMPASS Pathways from Outperform to In-line and set a new price target of $6.00 from $11.00 previously

    6/23/25 9:15:38 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on COMPASS Pathways with a new price target

    Stifel initiated coverage of COMPASS Pathways with a rating of Buy and set a new price target of $11.00

    2/27/25 6:17:48 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    SEC Filings

    View All

    COMPASS Pathways Plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - COMPASS Pathways plc (0001816590) (Filer)

    1/7/26 6:35:55 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by COMPASS Pathways Plc

    SCHEDULE 13G/A - COMPASS Pathways plc (0001816590) (Subject)

    11/14/25 4:37:38 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by COMPASS Pathways Plc

    10-Q - COMPASS Pathways plc (0001816590) (Filer)

    11/4/25 6:30:56 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    Leadership Updates

    Live Leadership Updates

    View All

    Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

    Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TR

    4/29/25 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways appoints Lori Englebert as Chief Commercial Officer

    New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatmentLatest of several key executive team hires, rounding out team to take Compass through phase 3 and beyond LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Lori Englebert as Chief Commercial Officer, effective July 8, 2024. She will be based in the company's New York City office. Lori brings multifaceted experience in global ph

    6/26/24 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways appoints Teri Loxam as Chief Financial Officer

    LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer (CFO), effective the beginning of March 2024. She will be based in the company's New York City office. Teri will serve as an advisor during the period leading up to her appointment as CFO.  Teri brings to Compass deep and extensive strategic experience working for publicly traded companies, in the pharmaceutical and biotechnology sectors, and beyond. She joins the company from Gameto, where she was CFO and played a

    12/7/23 7:00:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    Financials

    Live finance-specific insights

    View All

    Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

    Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter ended September 30, 2025, and provide an update on recent developments, on November 4, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on November 4, 2025. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/698442687. The webcast will be archived for 30 days. About Compass Pathways Compass Pathw

    10/28/25 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025

    Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter ended June 30, 2025, and provide an update on recent developments, on July 31, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on July 31, 2025. A live webcast of the call will be available on the Compass Pathways website at: Second Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:

    7/22/25 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

    Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2025, and provide an update on recent developments, on May 8, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2025. A live webcast of the call will be available on the Compass Pathways website at: First Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is

    4/28/25 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

    SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

    11/14/24 4:35:16 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

    SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

    11/14/24 4:20:24 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by COMPASS Pathways Plc

    SC 13G - COMPASS Pathways plc (0001816590) (Subject)

    4/11/24 4:04:21 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care